ESH Video


October 21, 2022


2nd How I Manage



Save the date: September 29 - October 1, 2023

Berlin, Germany



Chairs: Ulrich Jäger (Vienna),
Marie José Kersten (Amsterdam), Loretta Nastoupil (Houston)


About the Conference:

CAR-T cells and bispecific antibodies have advanced our therapeutic armamentarium for haematological malignancies.

The programme of this ESH conference aims to provide an overview of the benefits and risks of currently available therapies for acute lymphoblastic leukaemia, lymphoma and multiple myeloma. Special focus will be placed on the advantages and disadvantages of bispecific antibodies vs. cellular therapies (including T cells, NK cells and transplant strategies). Future perspectives regarding applications in other haematological malignancies and in solid tumours will also be discussed.

The format of the meeting is based on the analysis and discussion of clinical case studies. It will adopt a problem-solving approach, addressing practical considerations and guidelines. Emphasis will be placed on open discussion, including a maximum level of interaction between faculty and registered participants.

In addition to the scientific and medical issues addressed during the conference, the questions of affordability of and access to these novel expensive treatments will be tackled by medical experts, representatives of patient organisations, economists, authorities and industry.

Stay tuned, registration will open soon!



The programme will include:

Keynote Lecture - Plenary Sessions
Meet the Expert Sessions - Roundtables
Debates - Mentored Poster Walks
Brief Oral Communications

For more information, click here!